Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies - Scorecard - MDSpire

Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies

  • By

  • Boming Cao

  • Jingyi Pei

  • Ling Kong

  • Ying Han

  • Guangli Yan

  • Xijun Wang

  • June 11, 2026

  • 0 min

Share

Clinical Scorecard: Interconnected Mechanisms of Hypertension and Dyslipidemia in Cardiovascular Disease Development: Advancing Targeted Treatment Approaches

At a Glance

CategoryDetail
Condition
Key MechanismsRAAS/PPAR axis, AMPK/SIRT1 signaling, NLRP3 inflammasome activation
Target Population
Care Setting

Key Highlights

  • Hypertension and dyslipidemia synergistically accelerate cardiovascular diseases.
  • Multi-pathway molecular network contributes to CVD progression.

Guideline-Based Recommendations

Diagnosis

  • Assess blood pressure and lipid profiles in patients at risk for CVD.

Management

  • Implement multi-target therapeutic strategies addressing both hypertension and dyslipidemia.

Monitoring & Follow-up

  • Regularly monitor cardiovascular risk factors and treatment efficacy.

Risks

  • Increased risk of cardiovascular events due to the interplay of hypertension and dyslipidemia.

Patient & Prescribing Data

Patients with coexisting hypertension and dyslipidemia.

Combination therapies may improve hemodynamic and lipid profiles.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies

    • by Boming Cao, Jingyi Pei, Ling Kong, Ying Han, Guangli Yan, Xijun Wang

    • June 11, 2026

    Related Content

    AD Not Linked to Early CV Risk Markers

    Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

    When Bad Data Enters the Drug Pipeline

    Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

    Ensitrelvir Reduced COVID After Household Exposure

    In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.